Patents Assigned to Taisho Pharmaceutical Co., Ltd.
-
Patent number: 8258133Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: October 7, 2011Date of Patent: September 4, 2012Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Akito Yasuhara, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
-
Publication number: 20120220767Abstract: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase ? inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.Type: ApplicationFiled: October 4, 2010Publication date: August 30, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tetsuya Yabuuchi, Yusuke Oka, Shoichi Kuroda, Takahiro Oi, Yoshinori Sekiguchi
-
Publication number: 20120214990Abstract: A nitrogen-containing heterocyclic compound or pharmaceutically acceptable salt thereof represented by the general formula: which have a potent antibacterial activity and a high safety. Thus, the compounds are useful as antibacterial agents against gram-positive bacteria, gram-negative bacteria and drug resistant bacteria.Type: ApplicationFiled: May 3, 2012Publication date: August 23, 2012Applicants: TAISHO PHARMACEUTICAL CO., LTD., TOYAMA CHEMICAL CO., LTD.Inventors: Taro KIYOTO, Tadashi Tanaka, Yasuhiro Tsutsui, Junichi Ando, Mai Motono, Yasuko Kawaguchi, Toshiya Noguchi, Yasunobu Ushiki, Fumihito Ushiyama, Hiroki Urabe
-
Publication number: 20120190886Abstract: A composition for lowering a blood uric acid level is characterized by comprising taurine as an active ingredient.Type: ApplicationFiled: September 10, 2010Publication date: July 26, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Fuminori Kimura, Hideaki Kitajima, Takao Tanaka, Toru Nishikawa
-
Patent number: 8222417Abstract: The present invention provides compounds having excellent 11?-HSD1 inhibitory activity. A compound represented by the following formula (I): [wherein X1 represents an oxygen atom, or the formula —(CR11R12)p—, etc., Y1 represents a hydrogen atom, a hydroxyl group, etc., Z1 represents an oxygen atom or the formula —(NR14)—, R1 represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkyl group substituted with 1 to 3 halogen atoms, a C1-4 alkoxy group, a C1-4 alkoxycarbonyl group, a carboxyl group, a carbamoyl group, or an amino group, and m represents an integer of 1 or 2, and R2 represents a hydrogen atom or a C1-4 alkyl group, and n represents an integer of 1 or 2].Type: GrantFiled: June 24, 2008Date of Patent: July 17, 2012Assignee: Taisho Pharmaceutical Co., LtdInventors: Ryo Suzuki, Ayako Mikami, Hiroaki Tanaka, Hiroshi Fukushima
-
Publication number: 20120172598Abstract: The present invention provides compounds having superior TAFIa inhibitory activity.Type: ApplicationFiled: September 17, 2010Publication date: July 5, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Hideaki Amada, Daisuke Matsuda, Ayako Bohno
-
Patent number: 8211908Abstract: Disclosed is a compound represented by the general formula: [wherein R1 represents an aryl or heterocyclic group which may be substituted or the like; X1 represents a C2-C4 alkylene group or the like; X2, X3 and X5 independently represent NH, a bond or the like; X4 represents a lower alkylene group, a bond or the like; Y1 represents a bivalent alicyclic hydrocarbon residue which may be substituted or a bivalent alicyclic amine residue which may be substituted; and Z1, Z2, Z3, Z4, Z5 and Z6 independently represent a nitrogen atom, a group represented by the formula: CH, or the like, provided that at least one of Z3, Z4, Z5 and Z6 represents a nitrogen atom] or a salt thereof, which is useful as an antibacterial agent.Type: GrantFiled: May 24, 2007Date of Patent: July 3, 2012Assignees: Toyama Chemical Co., Ltd., Taisho Pharmaceutical Co., Ltd.Inventors: Taro Kiyoto, Junichi Ando, Tadashi Tanaka, Yasuhiro Tsutsui, Mai Yokotani, Toshiya Noguchi, Fumihito Ushiyama, Hiroki Urabe, Hiromasa Horikiri
-
Patent number: 8193176Abstract: The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof: {wherein R1 and R2, which may be the same or different, each represent C1-C6 alkyl or C3-C8 cycloalkyl, or R1 and R2 are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C1-C6 alkyl), n represents an integer of 0 to 2, T represents a hydrogen atom, halogen or C1-C6 alkyl, and R represents formula (I): or the like}.Type: GrantFiled: November 22, 2010Date of Patent: June 5, 2012Assignee: Taisho Pharmaceutical Co., LtdInventors: Toshio Nakamura, Makoto Tatsuzuki, Dai Nozawa, Tomoko Tamita, Seiji Masuda, Hiroshi Ohta, Shuhei Kashiwa, Aya Fujino, Shigeyuki Chaki, Toshiharu Shimazaki
-
Patent number: 8183387Abstract: The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof: {wherein R1 and R2, which may be the same or different, each represent C1-C6 alkyl or C3-C8 cycloalkyl, or R1 and R2 are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C1-C6 alkyl), n represents an integer of 0 to 2, T represents a hydrogen atom, halogen or C1-C6 alkyl, and R represents formula (I): or the like}.Type: GrantFiled: November 22, 2010Date of Patent: May 22, 2012Assignee: Taisho Pharmaceutical Co., LtdInventors: Toshio Nakamura, Makoto Tatsuzuki, Dai Nozawa, Tomoko Tamita, Seiji Masuda, Hiroshi Ohta, Shuhei Kashiwa, Aya Fujino, Shigeyuki Chaki, Toshiharu Shimazaki
-
Patent number: 8124744Abstract: Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).Type: GrantFiled: May 1, 2007Date of Patent: February 28, 2012Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masato Kashimura, Madoka Kawamura, Toshifumi Asaka, Kiyoshi Takayama, Haruhisa Ogita
-
Publication number: 20120040898Abstract: A pharmaceutical composition comprising a combination of (A) a 1-thio-D-glucitol compound represented by the general formula (I) and (B) at least one member of the group consisting of biguanides, insulin secretagogues, insulin sensitizers, insulins, dipeptidyl peptidase IV inhibitors, ?-glucosidase inhibitors, and GLP-1 mimetics, has superior efficacy in preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus and yet it causes no appreciable side effects.Type: ApplicationFiled: April 16, 2010Publication date: February 16, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Teisuke Takahashi, Saeko Uchida
-
Patent number: 8115017Abstract: C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C1-6 alkyl group, Y represents a C1-6 alkylene group or —O—(CH2)n- (wherein n represents an integer of 1 to 5), and Z represents —CONHRA or —NHCONHRB (provided that when Z represents —NHCONHRB, n is not 1), wherein RA represents a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2, and RB represents a hydrogen atom or a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g.Type: GrantFiled: June 28, 2007Date of Patent: February 14, 2012Assignee: Taisho Pharmaceutical Co., LtdInventors: Hiroyuki Kakinuma, Takahiro Oi, Yohei Kobashi, Yuko Hashimoto, Hitomi Takahashi
-
Publication number: 20120028982Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
-
Patent number: 8106024Abstract: The present invention uses an RPN2 gene expression inhibitor as a cancer cell growth inhibitor, which further includes a drug showing an anti-cancer action if desired, and is administered in combination with atelocollagen if desired. In addition, the present invention is an anti-cancer agent including such cancer cell growth inhibitor.Type: GrantFiled: June 15, 2007Date of Patent: January 31, 2012Assignees: Taisho Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Japan as represented by President of National Cancer Center, Koken Co., Ltd.Inventors: Takahiro Ochiya, Kikuya Kato, Kimi Honma, Yasuji Ueda
-
Patent number: 8106194Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.Type: GrantFiled: January 6, 2005Date of Patent: January 31, 2012Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E. J. Kennis
-
Publication number: 20120022164Abstract: Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): (where R represents a group represented by the formula: —(CH2)4—S—CH2—CO2H, —(CH2)4—S—CH2—CO2CH3, —(CH2)4—C?C—CO2H, —CH2—S—(CH2)2—S—CH2—CO2H, or —CH2—S—(CH2)4—CO2H), so that storage stability and content uniformity of the compound of the formula (I) are ensured.Type: ApplicationFiled: July 25, 2011Publication date: January 26, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takayuki SATO, Yoshie SATO
-
Publication number: 20120022064Abstract: The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.Type: ApplicationFiled: February 5, 2010Publication date: January 26, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Toshio Nakamura, Seiji Masuda, Aya Futamura
-
Patent number: 8097708Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.Type: GrantFiled: February 7, 2007Date of Patent: January 17, 2012Assignees: Taisho Pharmaceutical Co., Ltd., Meiji Seika Kaisha, Ltd.Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Akira Manaka, Haruhisa Ogita, Jun Kurosaka, Madoka Kawamura, Masato Kashimura, Naoki Sasamoto, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara, Dai Kubota
-
Publication number: 20120010414Abstract: The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.Type: ApplicationFiled: March 19, 2010Publication date: January 12, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito Yasuhara, Shuji Yamamoto, Hiroshi Ohta, Yoshihisa Shirasaki, Kazunari Sakagami, Masato Hayashi, Tsuyoshi Shibata, Youichi Shimazaki, Yuko Araki, Kumi Abe, Xiang-Min Sun
-
Publication number: 20120004232Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: September 8, 2011Publication date: January 5, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari SAKAGAMI, Hiroshi OHTA, Atsuro NAKAZATO